Adjunct Antipsychotic with Chlorpromazine (Thorazine)
Augmenting chlorpromazine with another antipsychotic is not recommended based on current evidence and FDA labeling; instead, if chlorpromazine is inadequate, switch to a different antipsychotic monotherapy rather than combining agents.
Rationale Against Polypharmacy
The FDA label for chlorpromazine does not support or provide guidance for combining it with other antipsychotics 1. More importantly, neither the 2025 INTEGRATE international guidelines 2 nor the 2020 APA guidelines 3 recommend combining first-generation antipsychotics like chlorpromazine with other antipsychotics as a standard practice.
The most recent 2025 INTEGRATE guidelines specifically address augmentation strategies, but only in the context of clozapine - recommending augmentation with amisulpride, aripiprazole, or ECT when significant positive symptoms persist on clozapine 2. This is notably not applicable to chlorpromazine augmentation.
What to Do Instead
If Chlorpromazine is Ineffective:
- Switch to clozapine if the patient has treatment-resistant schizophrenia (failed adequate trials of other antipsychotics) 3
- Switch to a second-generation antipsychotic such as:
- Risperidone, quetiapine, or olanzapine based on side effect profile preferences
- Evidence shows comparable efficacy between chlorpromazine and these agents 4
If Specific Symptom Domains Persist:
- For persistent negative symptoms: Consider switching to cariprazine or aripiprazole, or low-dose amisulpride (50 mg twice daily) 2
- For cognitive symptoms: Reduce anticholinergic burden; chlorpromazine has high anticholinergic activity 2
Critical Safety Considerations
Combining antipsychotics increases risks without clear benefit:
- Additive extrapyramidal symptoms: Chlorpromazine already carries significant EPS risk 1, 4
- Increased anticholinergic burden: Chlorpromazine has substantial anticholinergic effects 2, 1
- Cumulative metabolic effects: Multiple antipsychotics compound cardiometabolic risks 1
- Enhanced CNS depression: Chlorpromazine intensifies CNS depressant effects 1
- Tardive dyskinesia risk: Increases with cumulative antipsychotic exposure 1
Common Pitfall to Avoid
Do not add a second antipsychotic to "boost" chlorpromazine's effect. The evidence base for antipsychotic polypharmacy is weak, and guidelines consistently recommend optimizing monotherapy or switching agents rather than combining them. The only exception supported by high-quality evidence is augmenting clozapine (not chlorpromazine) with specific agents 2.
If you're considering augmentation because of inadequate response, reassess the chlorpromazine dose (therapeutic range is typically 200-800 mg/day) 5, ensure adequate treatment duration, and verify adherence before adding complexity to the regimen.